| Keywords: |
single nucleotide polymorphism; genetics; review; cisplatin; diagnostic procedure; carboplatin; classification; gene expression profiling; tumor differentiation; genetic variability; attitude to health; pathology; transcriptomics; tumor marker; bladder tumor; urinary bladder neoplasms; histology; urologic neoplasms; urothelium; patient care; diagnosis; urothelial carcinoma; genomics; carcinoma, transitional cell; loss of function mutation; transitional cell carcinoma; transcriptome; tumor classification; molecular pathology; epithelial mesenchymal transition; taxonomy; urinary tract tumor; molecular classification; cancer prognosis; humans; human; pembrolizumab; whole exome sequencing; biomarkers, tumor; genetic profile; enfortumab vedotin; sacituzumab govitecan; trastuzumab deruxtecan
|
